Insurance Readiness Before Clinical or Commercial Activity

Coverage Must Follow the Risk Profile

The insurance program should be based on a documented assessment of activities, exposures, controls, and residual risk. That assessment should consider the likelihood and severity of loss, the company’s risk tolerance, control effectiveness, and which risks should be avoided, reduced, retained, transferred, or shared.

A clinical investigation may create sponsor, product, subject-injury, professional-services, shipment, privacy, and depot exposures. Insurance planning should reflect the company’s study role and risk allocation, including responsibility for investigational product control, safety reporting, protocol deviations, and subject injury. It should also address limits, exclusions, deductibles, territorial scope, and coverage requirements imposed by sites, research organizations, or clinical trial agreements.

Commercial activity creates a different risk profile. Product liability coverage should address claims arising from devices after they have been sold, distributed, or placed into use. Importation and distribution may also involve complaint handling, adverse-event escalation, recalls, returns, field actions, and business interruption. Insurance is a risk-transfer mechanism; it does not replace quality-system controls, traceability, recall planning, or escalation procedures.

Inventory, Facilities, and Personnel

A depot, warehouse, office, demonstration area, or consignment program introduces property, custody, continuity, and concentration risks. Coverage should be reviewed for customer-owned inventory, goods in transit, off-site stock, consigned products, temperature excursions, spoilage, power failure, theft, flood, and replacement costs. Limits and sub-limits should be compared with the maximum probable loss at any facility, vehicle, clinical site, or customer location.

Employees and representatives may add workers’ compensation, employers’ liability, commercial auto, cyber, privacy, employment-practices, and excess-liability exposures. The review should test whether existing controls reduce risk to an acceptable residual level and whether additional mitigation, contractual transfer, or higher limits are required.

Contracts Can Reallocate Risk

Distribution, clinical, lease, logistics, and customer agreements often require minimum limits, additional-insured status, waiver of subrogation, primary and non-contributory wording, territorial coverage, or extended reporting periods. These requirements should be reconciled with indemnities, liability caps, exclusions, and responsibility for recalls, product loss, subject injury, and data incidents. A certificate of insurance is evidence of a policy; it does not itself create required endorsements or coverage.

Insurance readiness requires confirmation that policies are bound, named insureds are correct, material activities and products have been disclosed, required endorsements have been issued, and remaining uninsured or underinsured risks have been consciously accepted before the first shipment, study procedure, hire, facility use, or customer commitment.

MDD Options can help manufacturers map clinical and commercial activities into a practical risk register, identify control gaps, and clarify which exposures remain with each party. Through its hybrid model, MDD Options can assume defined importing, depot, distribution, complaint, recall-support, and logistics functions within established U.S. infrastructure, reducing the manufacturer’s direct operational risk. MDD Options can also support coordination with the manufacturer’s broker, counsel, and commercial or study partners so that risk ownership, mitigation measures, insurance requirements, and residual risk are clearly documented.